Advertisement
NEW YORK, Fev. 8, 2018 /PRNewswire/ -- Read the full report: https://www.reportlinker.com/p05272931
SummaryCardiovascular disease (CVD) is a general term for a variety of different diseases and conditions affecting the heart or blood vessels. Cardiovascular events mostly occur as a result of the development of fatty deposits (atherosclerosis) in arteries obstructing blood flow to the brain, body or heart by causing a narrowing (stenosis) of blood vessels. Alternatively, blood clots can occur when part of an atherosclerotic plaque breaks off and either locally forms a thrombus, or travels down the blood stream and becomes blocked at a different point, forming an embolus.CVD is a complex disease with a wide variety of risk factors including those that are modifiable, such as physical inactivity, diet and smoking, and non-modifiable factors such as age (as atherosclerosis develops naturally over time), genes, congenital dispositions, and gender. In addition, these primary risk factors also expose one to an increased risk of developing secondary risk factors, primarily hypertension and dyslipidemia.CVD is the number one cause of death worldwide, with an estimated 17.7 Million deaths in 2015, with around 7.4 Million (over 41%) of these due specifically to CHD and about 6.7 Million (just over 39%) specifically due to stroke (WHO, 2017). The total economic impact of CVD, including both direct costs such as treatments and indirect costs such as productivity loss, is considerable and varies between countries. In the UK, total healthcare costs of CVD exceed $11 Billion annually, with annual economic costs of CVD exceeding $24 Billion annually (Townsend et al., 2012). In the US total costs associated with CVD were estimated to be as high as $656 Billion in 2015 and could rise to as high as $1.2 trillion by 2030.Novartis recently launched Entresto (valsartan plus sacubitril), which is indicated specifically for the treatment of left ventricular heart failure with reduced EF. Most classes of CVD medications are very well established and as such the market is now heavily genericized.Johnson & Johnson entered the market in 2008 with the approval of Xarelto, which Johnson & Johnson markets in the US via Janssen. Its share in revenue from this drug totaled $2.3 Billion in 2016 and this is expected to increase to $3.4 Billion by 2023. In January 2017, Johnson & Johnson acquired Actelion and with it Uptravi and Opsumit, which together will generate $5.4 Billion by 2023, enough to secure Johnson & Johnson's place as market leader.The report "Global Cardiovascular Disease Drugs Market to 2023 - Expiries, Acquisitions and New Products for Deep Vein Thrombosis, Pulmonary Arterial Hypertension and Dyslipidemia to Shake-Up the Competitive Landscape" provides an introduction to cardiovascular disease (CVD), including disease symptoms, diagnosis, etiology, pathophysiology, comorbidities and complications, epidemiology, prognosis and treatment.Specifically, this report includes -- Overview of the CVD marketed products landscape, including product profiles of key marketed products and revenue projections for each of these drugs.- Analyzes the CVD pipeline, detailing, among other parameters, drug distribution by stage of development, molecule type and molecular target, plus an analysis of the key indications in the pipeline: hypertension, dyslipidemia, heart failure and thrombotic events.- Presents forecast projections to 2023 on a global level, with forecasts provided for the US and aggregate revenue forecasts for the top five EU markets (the UK, France, Germany, Italy and Spain) and Japan. Additionally, revenue forecasts for the major molecular target classes in CVD are provided.- Assesses the company landscape in CVD, with an analysis of the key players, the types of company involved in this therapy area, and whether this therapy area comprises a large proportion of each company's pipeline portfolio and total revenues.- Analyzes trends in co-development and licensing deals relating to CVD products.Scope- With over 1,400 products in active development, the pipeline for CVD is extensive. Does current pipeline innovation hold the potential to change the CVD market in the near future?- The clinical trials process for CVD drugs is complex. What is the risk of a CVD drug failing to reach the market? What is the risk of a drug failing at a specific Phase?- The CVD market landscape is forecast to undergo a period of substantial change following key approvals, patent expiries and acquisitions. Which of the leading companies will have the highest market share by 2023? What strategies have these companies adopted to achieve market growth?- There has been a moderately high level of deal activity in recent years. How do deal frequency and value compare between target families and molecule types?Reasons to buy- Understand the current clinical and commercial landscape through a comprehensive analysis of disease symptoms, diagnostic methods, etiology, pathophysiology, comorbidities and complications, epidemiology, prognosis and treatment.- Recognize the leading therapeutics, as well as gaps in the market, with portfolios of key marketed products, including historical and forecast sales revenue patterns.- Identify trends and developments, in terms of molecule type and molecular target, within the overall CVD pipeline, as well as for key CVD indications: hypertension, heart failure, dyslipidemia and thrombotic events.- Consider market opportunities and potential risks by examining trends in clinical trial duration and size, as well as clinical trial failure rates, by stage of development, key indication, molecule type and molecular target.- Predict how the evolving treatment landscape will drive market growth to 2023 and understand the contributions that different products and companies will make to this growth.- Understand how strategic consolidations have shaped the current pipeline and marketed products landscape.Read the full report: https://www.reportlinker.com/p05272931
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ Contact Clare: [email protected] US: (339)-368-6001 Intl: +1 339-368-6001
Advertisement
View original content:http://www.prnewswire.com/news-releases/global-cardiovascular-disease-drugs-market-to-2023---expiries-acquisitions-and-new-products-for-deep-vein-thrombosis-pulmonary-arterial-hypertension-and-dyslipidemia-to-shake-up-the-competitive-landscape-300595996.html
SOURCE Reportlinker
